SIGNAL-DRIVEN SALES

Turn Funding Signals into Pipeline

Fundz analyzes real-time funding events through YOUR lens to surface companies most likely to buy — with the “why now” built in.

10–25 ICP-matched leads daily • Buyer-intent scoring • No duplicates

Every plan includes:

✓Signal-Driven Leads Based on YOUR ICP

✓Slack + Chrome real-time alerts

✓No duplicates — only new events

INDUSTRY FIRST

Replimune Secures $200 Million In Non-Dilutive Debt Financing From Hercules Capital, Inc.

Oct 07, 2022•almost 3 years ago

Amount Raised

$200 Million

WoburnBiotechnologyHealth Care

Description

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that it has obtained a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. This non-dilutive capital extends cash runway into 2025 ahead of key catalysts from the Company’s registration-directed CERPASS and IGNYTE trials in cutaneous squamous cell carcinoma (CSCC) and anti-PD1 failed melanoma inclusive of the costs of funding commercial infrastructure and the running of a confirmatory study to support a potential BLA filing in anti-PD1 failed melanoma.

Company News

(10 articles)

Thu, 18 Sep 2025 15:26:28 GMT

Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights - REPL - PR Newswire

Tue, 02 Sep 2025 07:00:00 GMT

Replimune Prepares for Type A Meeting With FDA on RP1 - Dermatology Times

Tue, 16 Sep 2025 22:11:00 GMT

REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman - PR Newswire

Tue, 22 Jul 2025 07:00:00 GMT

FDA Issues CRL to Replimune for Vusolimogene Oderparepvec With Nivolumab for Advanced Melanoma - Pharmacy Times

Wed, 30 Jul 2025 07:00:00 GMT

IGNYTE Trial Investigators Press FDA to Reconsider Replimune CRL Amid Promising Melanoma Data, Leadership Shakeup - Pharmaceutical Executive

Fri, 25 Jul 2025 07:00:00 GMT

FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors - Applied Clinical Trials

Tue, 22 Jul 2025 07:00:00 GMT

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm - Business Wire

Tue, 21 Jan 2025 08:00:00 GMT

FDA Grants Priority Review to Replimune's Melanoma Treatment RP1, Breakthrough Therapy Status Secured - Stock Titan

Wed, 03 Sep 2025 20:18:00 GMT

Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman - PR Newswire

Thu, 18 Sep 2025 15:32:04 GMT

Path Toward Accelerated Approval of RP1 in Advanced Melanoma Remains Unclear After FDA Type A Meeting - OncLive

FundzWatch™ Score

Medium Activity

Related People

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech